Please login to the form below

Not currently logged in

Vaccibody name Martin Bonde as CEO

He joins from EpiTherapeutics where he holds the same role

martin bonde vaccibodyNorwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.

Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma. 

He joins from EpiTherapeutics, where he has held the role of CEO since 2009.

Tom Pike, chairman of Vaccibody, said: "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making. 

“We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's' considerable potential”.

Bonde's experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.

1st July 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...